Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 8.40
IPSEY's Cash to Debt is ranked higher than
58% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. IPSEY: 8.40 )
Ranked among companies with meaningful Cash to Debt only.
IPSEY' s 10-Year Cash to Debt Range
Min: 1.56  Med: 9.15 Max: No Debt
Current: 8.4
Equity to Asset 0.62
IPSEY's Equity to Asset is ranked lower than
51% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IPSEY: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
IPSEY' s 10-Year Equity to Asset Range
Min: 0.28  Med: 0.62 Max: 0.66
Current: 0.62
0.28
0.66
F-Score: 9
Z-Score: 5.24
M-Score: -2.75
WACC vs ROIC
6.45%
18.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.62
IPSEY's Operating margin (%) is ranked higher than
76% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. IPSEY: 16.62 )
Ranked among companies with meaningful Operating margin (%) only.
IPSEY' s 10-Year Operating margin (%) Range
Min: 6  Med: 16.62 Max: 21.02
Current: 16.62
6
21.02
Net-margin (%) 11.52
IPSEY's Net-margin (%) is ranked higher than
70% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. IPSEY: 11.52 )
Ranked among companies with meaningful Net-margin (%) only.
IPSEY' s 10-Year Net-margin (%) Range
Min: -2.19  Med: 11.90 Max: 15.29
Current: 11.52
-2.19
15.29
ROE (%) 15.26
IPSEY's ROE (%) is ranked higher than
74% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. IPSEY: 15.26 )
Ranked among companies with meaningful ROE (%) only.
IPSEY' s 10-Year ROE (%) Range
Min: -2.92  Med: 16.36 Max: 30
Current: 15.26
-2.92
30
ROA (%) 9.38
IPSEY's ROA (%) is ranked higher than
75% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. IPSEY: 9.38 )
Ranked among companies with meaningful ROA (%) only.
IPSEY' s 10-Year ROA (%) Range
Min: -1.75  Med: 9.88 Max: 15.26
Current: 9.38
-1.75
15.26
ROC (Joel Greenblatt) (%) 52.80
IPSEY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. IPSEY: 52.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPSEY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.22  Med: 55.20 Max: 105.8
Current: 52.8
18.22
105.8
Revenue Growth (3Y)(%) 3.80
IPSEY's Revenue Growth (3Y)(%) is ranked lower than
59% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IPSEY: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPSEY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.3  Med: 4.45 Max: 5.8
Current: 3.8
-61.3
5.8
EBITDA Growth (3Y)(%) 23.50
IPSEY's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.40 vs. IPSEY: 23.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPSEY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.7  Med: -9.15 Max: 23.5
Current: 23.5
-55.7
23.5
EPS Growth (3Y)(%) 28.60
IPSEY's EPS Growth (3Y)(%) is ranked higher than
81% of the 450 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPSEY: 28.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPSEY' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.5  Med: 1.05 Max: 28.6
Current: 28.6
-20.5
28.6
» IPSEY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
IPSEY's P/E(ttm) is ranked higher than
60% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.70 vs. IPSEY: 27.60 )
Ranked among companies with meaningful P/E(ttm) only.
IPSEY' s 10-Year P/E(ttm) Range
Min: 3.01  Med: 20.27 Max: 2432.5
Current: 27.6
3.01
2432.5
PE(NRI) 27.60
IPSEY's PE(NRI) is ranked higher than
59% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.70 vs. IPSEY: 27.60 )
Ranked among companies with meaningful PE(NRI) only.
IPSEY' s 10-Year PE(NRI) Range
Min: 12.76  Med: 20.76 Max: 29.87
Current: 27.6
12.76
29.87
P/B 3.98
IPSEY's P/B is ranked lower than
57% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. IPSEY: 3.98 )
Ranked among companies with meaningful P/B only.
IPSEY' s 10-Year P/B Range
Min: 1.53  Med: 2.96 Max: 4.81
Current: 3.98
1.53
4.81
P/S 3.19
IPSEY's P/S is ranked higher than
51% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.27 vs. IPSEY: 3.19 )
Ranked among companies with meaningful P/S only.
IPSEY' s 10-Year P/S Range
Min: 0.46  Med: 2.12 Max: 3.65
Current: 3.19
0.46
3.65
PFCF 26.35
IPSEY's PFCF is ranked higher than
71% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.86 vs. IPSEY: 26.35 )
Ranked among companies with meaningful PFCF only.
IPSEY' s 10-Year PFCF Range
Min: 10.07  Med: 22.25 Max: 46.82
Current: 26.35
10.07
46.82
POCF 17.27
IPSEY's POCF is ranked higher than
71% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.88 vs. IPSEY: 17.27 )
Ranked among companies with meaningful POCF only.
IPSEY' s 10-Year POCF Range
Min: 2.4  Med: 11.58 Max: 20.56
Current: 17.27
2.4
20.56
EV-to-EBIT 17.96
IPSEY's EV-to-EBIT is ranked higher than
63% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. IPSEY: 17.96 )
Ranked among companies with meaningful EV-to-EBIT only.
IPSEY' s 10-Year EV-to-EBIT Range
Min: 1  Med: 15.00 Max: 26.3
Current: 17.96
1
26.3
PEG 3.58
IPSEY's PEG is ranked lower than
57% of the 249 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. IPSEY: 3.58 )
Ranked among companies with meaningful PEG only.
IPSEY' s 10-Year PEG Range
Min: 1.34  Med: 5.48 Max: 7.48
Current: 3.58
1.34
7.48
Shiller P/E 46.84
IPSEY's Shiller P/E is ranked lower than
60% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.44 vs. IPSEY: 46.84 )
Ranked among companies with meaningful Shiller P/E only.
IPSEY' s 10-Year Shiller P/E Range
Min: 6.91  Med: 23.55 Max: 46.95
Current: 46.84
6.91
46.95
Current Ratio 1.64
IPSEY's Current Ratio is ranked lower than
66% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. IPSEY: 1.64 )
Ranked among companies with meaningful Current Ratio only.
IPSEY' s 10-Year Current Ratio Range
Min: 1.39  Med: 1.92 Max: 2.33
Current: 1.64
1.39
2.33
Quick Ratio 1.38
IPSEY's Quick Ratio is ranked lower than
59% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. IPSEY: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
IPSEY' s 10-Year Quick Ratio Range
Min: 1.1  Med: 1.58 Max: 2.03
Current: 1.38
1.1
2.03
Days Inventory 131.48
IPSEY's Days Inventory is ranked lower than
61% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.04 vs. IPSEY: 131.48 )
Ranked among companies with meaningful Days Inventory only.
IPSEY' s 10-Year Days Inventory Range
Min: 133.64  Med: 160.26 Max: 176.3
Current: 131.48
133.64
176.3
Days Sales Outstanding 79.33
IPSEY's Days Sales Outstanding is ranked lower than
55% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.21 vs. IPSEY: 79.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPSEY' s 10-Year Days Sales Outstanding Range
Min: 76.21  Med: 79.24 Max: 80.78
Current: 79.33
76.21
80.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.69
IPSEY's Dividend Yield is ranked higher than
60% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. IPSEY: 1.69 )
Ranked among companies with meaningful Dividend Yield only.
IPSEY' s 10-Year Dividend Yield Range
Min: 1.39  Med: 2.50 Max: 4.36
Current: 1.69
1.39
4.36
Dividend Payout 0.27
IPSEY's Dividend Payout is ranked higher than
60% of the 394 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. IPSEY: 0.27 )
Ranked among companies with meaningful Dividend Payout only.
IPSEY' s 10-Year Dividend Payout Range
Min: 0.34  Med: 0.43 Max: 80
Current: 0.27
0.34
80
Yield on cost (5-Year) 1.91
IPSEY's Yield on cost (5-Year) is ranked higher than
56% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. IPSEY: 1.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IPSEY' s 10-Year Yield on cost (5-Year) Range
Min: 1.57  Med: 2.84 Max: 4.93
Current: 1.91
1.57
4.93
Share Buyback Rate 0.50
IPSEY's Share Buyback Rate is ranked higher than
83% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.30 vs. IPSEY: 0.50 )
Ranked among companies with meaningful Share Buyback Rate only.
IPSEY' s 10-Year Share Buyback Rate Range
Min: 0.5  Med: 0.10 Max: -187.2
Current: 0.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 178.11
IPSEY's Price/Net Current Asset Value is ranked lower than
100% of the 377 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.83 vs. IPSEY: 178.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IPSEY' s 10-Year Price/Net Current Asset Value Range
Min: 10.87  Med: 48.59 Max: 381.83
Current: 178.11
10.87
381.83
Price/Tangible Book 7.31
IPSEY's Price/Tangible Book is ranked lower than
72% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. IPSEY: 7.31 )
Ranked among companies with meaningful Price/Tangible Book only.
IPSEY' s 10-Year Price/Tangible Book Range
Min: 3.1  Med: 5.70 Max: 7.16
Current: 7.31
3.1
7.16
Price/Projected FCF 1.90
IPSEY's Price/Projected FCF is ranked higher than
66% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. IPSEY: 1.90 )
Ranked among companies with meaningful Price/Projected FCF only.
IPSEY' s 10-Year Price/Projected FCF Range
Min: 0.9  Med: 1.26 Max: 1.82
Current: 1.9
0.9
1.82
Price/Median PS Value 1.51
IPSEY's Price/Median PS Value is ranked lower than
62% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. IPSEY: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
IPSEY' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 1.07 Max: 1.65
Current: 1.51
0.22
1.65
Price/Peter Lynch Fair Value 1.68
IPSEY's Price/Peter Lynch Fair Value is ranked higher than
58% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. IPSEY: 1.68 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IPSEY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.4  Med: 1.41 Max: 1.41
Current: 1.68
1.4
1.41
Price/Graham Number 2.98
IPSEY's Price/Graham Number is ranked lower than
58% of the 359 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.57 vs. IPSEY: 2.98 )
Ranked among companies with meaningful Price/Graham Number only.
IPSEY' s 10-Year Price/Graham Number Range
Min: 1.65  Med: 2.17 Max: 2.57
Current: 2.98
1.65
2.57
Earnings Yield (Greenblatt) (%) 5.60
IPSEY's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. IPSEY: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPSEY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.8  Med: 6.70 Max: 103
Current: 5.6
3.8
103
Forward Rate of Return (Yacktman) (%) 19.10
IPSEY's Forward Rate of Return (Yacktman) (%) is ranked higher than
74% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.89 vs. IPSEY: 19.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPSEY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -43.5  Med: -4.00 Max: 19.8
Current: 19.1
-43.5
19.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:0MH6.UK, IPNNV.France, IPN.France, I7G.Germany,
Ipsen SA was incorporated on July 28, 1998. It is a biotechnology specialty care company. It produces drugs for uro-oncology, endocrinology, neurology and hematology, and primary care. The Company's segments include Major Western European countries, including France, Italy, Spain, the United Kingdom, and Germany; Rest of Europe, including all other Western and Eastern European countries; North America, mainly including the United States; and Rest of the World, encompassing all countries.
» More Articles for IPSEY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Ipsen Provides an Update on 2020 Strategy and Outlook at Investor Day Jul 02 2015
Ipsen initiates a share buyback program Jun 02 2015
Ipsen confirms its eligibility for PEA-PME Jun 01 2015
Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015 May 28 2015
Ipsen Strengthens Its Presence in the Oncology Field with the Acquisition of OctreoPharm Sciences, a... May 19 2015
Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic... May 14 2015
Ipsen S.A. upgraded by Natixis Bleichroeder Apr 29 2015
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year Apr 29 2015
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in... Apr 16 2015
Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in... Apr 16 2015
Ipsen Biopharmaceuticals expands to Canada Apr 15 2015
Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for... Apr 08 2015
Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement Apr 01 2015
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical... Apr 01 2015
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to... Mar 18 2015
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to... Mar 18 2015
Paulson & Co. ups position in Allergan Mar 06 2015
Ipsen’s 2014 Results and 2015 Financial Objectives Mar 03 2015
Dominique Laymand is Appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance... Mar 02 2015
Ipsen Enters into Option Agreement to Acquire Canbex Therapeutics Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK